Drug Profile
Aponermin - Beijing Sunbio Biotech
Alternative Names: Circularly Permuted TRAIL - Beijing Sunbio Biotech; CPT - Beijing Sunbio Biotech; Human recombinant Apo2L/TRAIL - Beijing Sunbio Biotech; Human recombinant circularly permuted TRAIL - Beijing Sunbio Biotech; Human recombinant CPT - Beijing Sunbio Biotech; Recombinant Apo2L - Beijing Sunbio Biotech; ShaiteLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Beijing Sunbio Biotech
- Class Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Multiple myeloma
- No development reported Solid tumours
Most Recent Events
- 02 Nov 2023 Beijing Sunbio Biotech has patent protection for aponermin and its related core technologies in many undisclosed countries worldwide
- 02 Nov 2023 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in China (IV) - First global approval
- 02 Nov 2023 Beijing Sunbio Biotech intends to launch aponermin in China